ALAN KEARNS: Open Payments
NPI 1619128634 · YAKIMA, WA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$299 in 14 payments from 6 companies in 2025. Trend: 2023 $938 · 2024 $768 · 2025 $299
Food & beverage: $215Education: $84
| Company | Payments | Amount |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 7 | $184 |
| Neurocrine BioSciences, Inc. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $30 |
| Alkermes, Inc. | 1 | $20 |
| Janssen Pharmaceuticals, Inc | 1 | $17 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $14 |
Products named: UZEDY, INGREZZA, REXULTI, ARISTADA, INVEGA SUSTENNA, CAPLYTA.
Industry payments across WA — which companies pay providers there.
